Treatment of Ascites

1. General/first-line measures (grade 1-2, uncomplicated ascites)

• Sodium restriction: less than ~2000 mg (88 mmol)/day of dietary sodium. Fluid restriction is only added if serum sodium is significantly low (<125 mmol/L).
• Diuretics (mainstay of medical therapy):
  • Spironolactone (aldosterone antagonist) is the diuretic of choice for cirrhotic ascites, started around 100 mg/day, since hyperaldosteronism drives the sodium retention.
  • Furosemide (loop diuretic, typically 40 mg/day) is added, especially if peripheral edema coexists, usually in a step-up combination (commonly a 100:40 mg spironolactone:furosemide ratio) titrated up to maximums of about spironolactone 400 mg/day and furosemide 160 mg/day.
  • Oral furosemide is preferred over IV, since IV dosing can worsen renal function.
  • Weight loss goal: about 0.5 kg/day without edema, up to ~1 kg/day with edema; fluid removal should not exceed roughly 500 mL/day if edema is absent, to avoid intravascular depletion and azotemia.
  • Avoid NSAIDs, ACE inhibitors, and ARBs, which worsen renal perfusion and sodium retention (Bailey and Love's Short Practice of Surgery, p. 2511-2519; Rosen's Emergency Medicine, p. 2965-2977).

2. Refractory or tense ascites

• Large-volume paracentesis (LVP) with albumin replacement is first-line for tense or diuretic-refractory ascites. Albumin (6-8 g per liter of ascites removed) is given when ≥5 L is removed to prevent post-paracentesis circulatory dysfunction (electrolyte disturbance, renal impairment, hyponatremia). Some protocols cap sessions at <8 L with proportionally higher albumin dosing.
  • Technique: needle entry ~3 cm medial and 3 cm superior to the left anterosuperior iliac spine (left side preferred over right to avoid a lactulose-distended cecum), using an angled or Z-track approach to reduce post-procedure leakage; ultrasound guidance improves safety.
• Transjugular intrahepatic portosystemic shunt (TIPS): decompresses portal hypertension and is more effective than repeated LVP at controlling refractory ascites, but carries risk of hepatic encephalopathy and requires adequate hepatic reserve.
• Vasoconstrictors: midodrine (an oral alpha-1 agonist) can be as effective as albumin for post-LVP hemodynamic stabilization and may improve diuretic responsiveness; octreotide (somatostatin analogue) is used adjunctively, particularly in hepatorenal syndrome.
• Non-selective beta-blockers (propranolol, nadolol) for variceal prophylaxis should be continued cautiously in refractory ascites and reduced/stopped if hypotension (<90/60 mmHg), hyponatremia, or acute kidney injury develops, since they can precipitate circulatory dysfunction.
• Peritoneovenous shunt: an older option, now rarely used given TIPS and transplantation.
• Liver transplantation is the only definitive treatment; refractory ascites carries roughly 50% one-year mortality without transplant, so eligible patients should be referred early (Current Surgical Therapy, p. 1806-1826).

3. Ruling out infection

4. Malignant/other causes

Emerging evidence (2025-2026, not yet standard of care)

• SGLT2 inhibitors are being studied for a possible role in ascites management and slowing disease progression in cirrhosis (PMID: 40429923, 2025 systematic review) - promising but not yet part of guideline-directed therapy.
• A 2026 meta-analysis reassessed human albumin solution use across cirrhosis complications including ascites (PMID: 41543475), broadly supporting albumin's established role but refining outcome data.